Serum Level of the Soluble Form of the CD30 Molecule Identifies Patients With Hodgkin’s Disease at High Risk of Unfavorable Outcome

Preliminary reports suggested a prognostic significance for serum levels of soluble CD30 (sCD30) in patients with Hodgkin’s disease (HD). In this study, we investigated the prognostic impact of sCD30 concentration at diagnosis in relation to the other recognized prognostic parameters in 303 patients...

Full description

Saved in:
Bibliographic Details
Published in:Blood 1998-04, Vol.91 (8), p.3011-3016
Main Authors: Nadali, Gianpaolo, Tavecchia, Luisa, Zanolin, Elisabetta, Bonfante, Valeria, Viviani, Simonetta, Camerini, Edgarda, Musto, Pellegrino, Di Renzo, Nicola, Carotenuto, Mario, Chilosi, Marco, Krampera, Mauro, Pizzolo, Giovanni
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Biological and medical sciences
Biomarkers, Tumor
Child
Female
Hematologic and hematopoietic diseases
Hodgkin Disease - blood
Hodgkin Disease - mortality
Hodgkin Disease - pathology
Hodgkin Disease - physiopathology
Humans
Ki-1 Antigen - blood
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Male
Medical sciences
Middle Aged
Prognosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Preliminary reports suggested a prognostic significance for serum levels of soluble CD30 (sCD30) in patients with Hodgkin’s disease (HD). In this study, we investigated the prognostic impact of sCD30 concentration at diagnosis in relation to the other recognized prognostic parameters in 303 patients with HD observed in three different institutions between 1984 and 1996. sCD30 levels were correlated with stage, presence of B symptoms, and tumor burden. High sCD30 levels entailed a higher risk of poor outcome, and the event-free survival (EFS) probability at 5 years for patients with sCD30 levels ≥100 and less than 100 U/mL was 59.9% (95% confidence interval [CI], 40.6% to 65.9%) and 87.5% (95% CI, 81.5% to 91.6%), respectively (P < .001). On the basis of the results of univariate analysis of 14 pretreatment characteristics, we included five prognostic factors (high sCD30 serum level, stage III-IV, B symptoms, low hemoglobin level, and age ≥50 years) into a multivariate model. High sCD30 and advanced stage were independently associated with an unfavorable prognosis. Their combined evaluation identified patients at high risk (stages III and IV and sCD30 ≥100 U/mL: EFS, 46.9%) and low risk (stages I and II with sCD30
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V91.8.3011.3011_3011_3016